Acute delirium induced by intravenous trimethoprim-sulfamethoxazole therapy in a patient with the acquired immunodeficiency syndrome.
The development of a rash in response to trimethoprim-sulfamethoxazole (TMP-SMX) administration is a frequent adverse reaction in people with the acquired immunodeficiency syndrome (AIDS). In contrast, there are no published reports in the English language literature describing TMP-SMX induced delirium in an AIDS patient. This report describes the development of frank delirium in a person with AIDS receiving TMP-SMX. The episode resolved completely within 72 h of withdrawal of the drug.
Salkind
A R
AR
Division of Infectious Diseases, University of Missouri-Kansas City School of Medicine, 64108, USA.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000208:Acute Disease; D000666:Amphotericin B / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003693:Delirium / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000666:Amphotericin B; D015662:Trimethoprim, Sulfamethoxazole Drug Combination